Brokerages expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to post ($0.20) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.21). Infinity Pharmaceuticals reported earnings per share of ($0.34) during the same quarter last year, which would suggest a positive year over year growth rate of 41.2%. The business is expected to announce its next quarterly earnings results on Thursday, August 2nd.

On average, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.74) per share for the current year, with EPS estimates ranging from ($0.77) to ($0.71). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.88) to ($0.59). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18).

Separately, Zacks Investment Research lowered shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday.

INFI traded up $0.01 on Friday, hitting $2.11. The company had a trading volume of 11,003 shares, compared to its average volume of 686,712. The firm has a market cap of $115.50 million, a P/E ratio of -2.54 and a beta of 2.50. Infinity Pharmaceuticals has a 1 year low of $2.11 and a 1 year high of $2.13.

In related news, major shareholder Value Fund L. P. Biotechnology acquired 1,510,000 shares of Infinity Pharmaceuticals stock in a transaction that occurred on Tuesday, April 10th. The shares were purchased at an average cost of $1.97 per share, for a total transaction of $2,974,700.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 11.45% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BVF Inc. IL increased its stake in Infinity Pharmaceuticals by 24.2% during the fourth quarter. BVF Inc. IL now owns 9,766,508 shares of the biotechnology company’s stock worth $19,826,000 after purchasing an additional 1,900,400 shares during the period. Millennium Management LLC increased its stake in Infinity Pharmaceuticals by 105.3% during the fourth quarter. Millennium Management LLC now owns 1,198,854 shares of the biotechnology company’s stock worth $2,434,000 after purchasing an additional 614,806 shares during the period. Wasatch Advisors Inc. purchased a new stake in Infinity Pharmaceuticals during the first quarter worth about $747,000. Dimensional Fund Advisors LP increased its stake in Infinity Pharmaceuticals by 76.2% during the first quarter. Dimensional Fund Advisors LP now owns 734,272 shares of the biotechnology company’s stock worth $1,542,000 after purchasing an additional 317,583 shares during the period. Finally, GSA Capital Partners LLP increased its stake in Infinity Pharmaceuticals by 2,112.9% during the first quarter. GSA Capital Partners LLP now owns 302,154 shares of the biotechnology company’s stock worth $635,000 after purchasing an additional 288,500 shares during the period. Hedge funds and other institutional investors own 47.35% of the company’s stock.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.